Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.32 |
| ▸ | REN | P00797 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | YAP1 | P46937 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1228593 | 0.90 | REN (0.34) | RENCNR1CNR2KCNH2CYP3A4 | |
| SCHEMBL1229668 | 0.79 | REN (0.49) | RENKCNH2CYP3A4 | |
| SCHEMBL16966249 | 0.76 | REN (0.45) | RENKCNH2CYP3A4 | |
| SCHEMBL1228594 | 0.67 | REN (0.54) | RENKCNH2CYP3A4 | |
| SCHEMBL3108333 | 0.66 | REN (0.48) | RENKCNH2CYP3A4 | |
| SCHEMBL173439 | 0.64 | PDE4B (0.41) | — | |
| SCHEMBL19743146 | 0.63 | ALDH1A1 (0.40) | — | |
| SCHEMBL2846672 | 0.62 | P2RX3 (0.46) | GPR119P2RX3 | |
| SCHEMBL6411744 | 0.62 | SLC2A1 (0.49) | GPR119YAP1 | |
| SCHEMBL5223609 | 0.62 | USP2 (0.41) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |